Personalised cancer treatments and innovative biopharma
Kite, which was purchased by Gilead, an American biopharmaceutical company, for 12 billion USD in 2017, is an international leader in highly personalised cancer treatments. Its new 117,000-square-foot facility will be situated within the SEGRO Park Amsterdam Airport, in Hoofddorp near Amsterdam Airport Schiphol. From here, Kite will engineer and produce innovative cell therapies and personalised cancer treatments, including axicabtagene ciloleucel, a Chimeric Antigen Receptor T cell (CAR T) therapy that is currently under review by the European Medicines Agency, and which is approved in the United States. It is expected that 300 new jobs will be created by 2020.
Upon the announcement, John F. Milligan, PhD, Gilead’s President and Chief Executive Officer, said: “We are pleased to be leading a new frontier of cancer innovation that is bringing hope for people living with cancer. This new European manufacturing facility will enable personalised cell therapies to be manufactured in closer geographic proximity to the patients who will receive them, potentially shortening the turnaround time for people who urgently need care.”
Life sciences and health in the Amsterdam Area
The life sciences and health sector in Amsterdam is going from strength to strength. In 2019, the European Medicines Agency will move from London to Amsterdam. It joins other major institutes including the Netherlands Cancer Institute (NKI), the Sanquin Blood Supply Foundation and ACTA (one of the top dental education and research facilities in the world). Amsterdam Science Park has proved itself as a fantastic incubator of both businesses and young talent, while more and more life sciences companies are choosing the areas around Amsterdam Airport Schiphol and the Port of Amsterdam due to the potential of these outstanding logistics hubs.